Annexon Bioscience, a Redwood City, Calif.-based developer of novel disease modifying drugs for neurodegenerative and autoimmune disorders, closed a $34m Series A-1 funding round.
The round was led by Novartis Venture Funds with participation from Satter Investment Management, LLC, and Clarus Ventures, LLC.
The company intends to use the funds for the development of its lead candidate, ANX005, for the treatment of neurodegenerative and autoimmune disorders.
Co-founded in 2011 by Ben Barres, MD, PhD, Professor and Chair of Neurobiology at Stanford University School of Medicine, and Arnon Rosenthal, PhD, Co-founder and CEO of Alector, and Co-founder, former President and CSO of Rinat Neurosciences, and led by Doug Love, CEO, Annexon is advancing development of classical complement pathway inhibitors for the treatment of neurodegenerative and autoimmune diseases.
FinSMEs
15/12/2014